Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L-DOPA in the rat striatum

Pharmacological Reports

Volumn 60, Issue 3, 2008, Pages 319-330

  Gołembiowska, Krystyna ^a   Dziubina, Anna ^a   Kowalska, Magdalena ^a   Kamińska, Katarzyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adenosine; Hydroxyl radical; In vivo microdialysis; L DOPA

Indexed keywords

1,3,7 TRIMETHYL URIC ACID; 2 CHLOROADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 HYDROXYBENZOIC ACID; 6 N CYCLOPENTYLADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; BENSERAZIDE; CAFFEINE; CAFFEINE DERIVATIVE; DOPAMINE; HYDROXYL RADICAL; LEVODOPA; PROTOCATECHUIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; FENTON REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; NEUROPROTECTION; NONHUMAN; RAT;

EID: 49349111331     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. 2 adenosine receptors in cultured cortical astrocytes. Br J Pharmacol, 2004, 141, 935-942.
2. Almeida CO, de Mendonça A, Cunha RA, Ribeiro JA: Adenosine promotes neuronal recovery from reactive oxygen species induced lesion in rat hippocampal slices. Neurosci Lett, 2003, 339, 127-130.
3. Asanuma M, Miyazaki I, Ogawa N: Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res, 2003, 5, 165-176.
4. Ascherio A, Chen H: Caffeinated clues from epidemiology of Parkinson's disease. Neurology, 2003, 61, S51-S54.
5. Beal MF, Shults CW: Effects of coenzyme Q10 in Huntington's disease and early Parkinson's disease. Biofactors, 2003, 18, 153-161.
6. Berthou F, Guillois B, Riche C, Dreano Y, Jacqz-Aigrain E, Beaune P: Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. Xenobiotica, 1992, 22, 671-680.
7. Bishnoi M, Chopra K, Kulkarni SK: Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia. Pharmacol Rep, 2007, 59, 181-191.
8. Brigelius-Flohe R: Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med, 1999, 27, 951-965.
9. 2 receptors have to do with it? Trends Neurosci, 2006, 29, 167-174.
10. 2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett, 1998, 429, 139-142.
11. 3H]NECA in rat striatal membranes. Mol Pharmacol, 1986, 29, 331-346.
12. Cadet JL, Brannock C: Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int, 1998, 32, 117-131.
13. Castagnoli N, Petzer JP, Steyn S, Castagnoli K, Chen J-F, Schwarzschild MA, Van der Schyf CJ: Monoamine oxidase B inhibition and neuroprotection. Neurology, 2003, 61, S62-S68.
14. 1 adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100 β protein from cultured astrocytes. Glia, 1999, 27, 275-281.
15. Chen Y-K, Lin H-C, Liu J-C, Wan F-J: Potent, hydroxyl radical-scavenging effect of apomorphine with iron and dopamine perfusion in rat striatum. Brain Res, 2001, 896, 165-168.
16. Cohen G: Oxy-radical toxicity in catecholamine neurons. Neurotoxicology, 1984, 5, 77-82.
17. 2A receptor blockade. Purinergic Signal, 2005, 1, 111-134.
18. Daniel WA, Kot M, Wj́cikowski J: Effects of classic and newer antidepressants on the oxidation pathways of caffeine in rat liver. In vitro study. Pol J Pharmacol, 2003, 55, 1045-1053.
19. de Mendonça A, Sebastião AM, Ribeiro JA: Adenosine: does it have a neuroprotective role at all? Brain Res Rev, 2000, 33, 258-274.
20. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC: Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol, 1996, 118, 1461-1468.
21. Fiacco TA, McCarthy KD: Intracellular astrocyte calcium waves in situ increase the frequency of spontaneous AMPA receptor currents in CA 1 pyramidal neurons. J Neurosci, 2004, 24, 722-732.
22. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams A: IV. Nomenclature and classification of purinoceptors. Pharmacol Rev, 1994, 46, 143-156.
23. Gabryel B, Malecki A: Ebselen attenuates oxidative stress in ischemic astrocytes depleted of glutathione. Comparison with glutathione precursors. Pharmacol Rep, 2006, 58, 381-392.
24. 2A receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology, 2004, 47, 414-426.
25. Gołembiowska K, Zylewska A: Adenosine receptors - the role in modulation of dopamine and glutamate release in the rat striatum. Pol J Pharmacol, 1997, 49, 317-322.
26. Halliwell B: Oxidative stress and neurodegeneration: where are we now? J Neurochem, 2006, 97, 1634-1658.
27. Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine, 4th edn., Oxford University Press, Oxford, 2006.
28. Hayton SM, Muller DP: Vitamin E in neural and visual function. Ann NY Acad Sci, 2004, 1031, 263-270.
29. Herrera AJ, Tomás-Camardiel M, Venero JL, Cano J, Machado A: Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic cells. J Neural Transm, 2005, 112, 111-119.
30. 2A receptor mRNA expression in Parkinson's disease. Neurosci Lett, 2000, 291, 54-58.
31. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N: Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res, 1999, 838, 51-59.
32. Ihan A, Akyol O, Gurel A, Armutcu F, Iraz M, Oztas E: Protective effects of caffeic acid phenethyl ester against experimental allergic encephalomyelitis-induced oxidative stress in rats. Free Radic Biol Med, 2004, 37, 386-394.
33. Jacobson KA, van Rhee AM: Development of selective purinoceptor agonists and antagonists. In: Purinergic Approaches in Experimental Therapeutics. Ed. Jacobson KA, Jarvis MF, Wiley-Liss, New York, USA, 1997, 101-128.
34. Kellog EWI, Fridovich I: Liposome oxidation and erythrocyte lysis by enzymatically generated superoxide and hydrogen peroxide. J Biol Chem, 1997, 252, 6721-6728.
35. Lauderback CM, Drake J, Zhou D, Hackett JM, Castegna A, Kanski J, Tsoras M et al.: Derivatives of xanthic acid are novel antioxidants: application to synaptosomes. Free Radic Res, 2003, 37, 355-365.
36. Lee C: Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorbing capacity and inhibition of LDL peroxidation. Clin Chim Acta, 2000, 295, 141-154.
37. 2A adenosine receptors. Life Sci, 2001, 68, 1343-1350.
38. Liu QS, Xu Q, Arcuino G, Kang J, Niedergaard M: Astrocyte mediated activation of neuronal kainate receptors. Proc Natl Acad Sci USA, 2004, 1201, 3172-3177.
39. Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci, 2005, 28, 57-87.
40. 2A receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotox Res, 2001, 3, 545-556.
41. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. Ed. Paxinos G, Watson C, Academic Press, San Diego, USA, 1998.
42. 2A receptor mRNA by dopamine denervation. Eur J Pharmacol, 2002, 446, 75-82.
43. 2A receptor antagonists as neuroprotective agents. Curr Med Chem - CNS Agents, 2004, 4, 35-45.
44. Ralevic V, Burnstock G: Receptors for purines and pyrimidines. Pharmacol Rev, 1998, 50, 413-492.
45. Rathbone MP, Middlemiss PJ, Gysbers JW, Andrew C, Herman MAR, Reed JK, Ciccarelli R et al.: Trophic effects of purines in neurons and glial cells. Prog Neurobiol, 1999, 59, 663-690.
46. Rice ME: Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci, 2000, 23, 209-216.
47. 2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem, 2005, 95, 919-929.
48. 2A receptor antagonists in animal models of Parkinson's disease. Neurology, 2003, 61, S55-S61.
49. Sharpe MA, Robb SJ, Clark JB: Nitric oxide and Fenton/Haber-Weiss chemistry: nitric oxide is a potent antioxidant at physiological concentrations. J Neurochem, 2003, 87, 386-394.
50. Smythies J: The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review - discussion. Neurotox Res, 1999, 1, 27-39.
51. 2A receptor antagonists in Parkinson's disease. Pharmacol Ther, 2005, 105, 267-310.
52. Zetterström T, Fillenz M: Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. Eur J Pharmacol, 1990, 180, 137-143.
53. Zetterström T, Sharp T, Collin AK, Ungerstedt U: In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur J Pharmacol, 1988, 148, 327-334.